MedTrace Logo

A Drug-Drug Interaction Study of Ambroxol and Levodropropizine

NCT01573663 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2012-07-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the drug-durg interaction between ambroxol and levodropropizine.

Conditions

  • Healthy

Interventions

DRUG

Ambroxol and Levodropropizine

Ambroxol HCl 30mg \& Levodropropizine 60mg, PO, Single dose

DRUG

Ambroxol

Ambroxol HCl 30mg, PO, single dose

DRUG

Levodropropizine

Levodropropizine 60mg, PO, single dose

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Wooseong Huh, MD · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01573663 on ClinicalTrials.gov